, 가톨릭대학교 의과대학 신경과학교실 2. Antithrombotic therapy (warfarin or aspirin) is recommended to prevent stroke in patients with nonvalvular AF according to assessment of their absolute stroke risk, estimated bleeding risk, patient preferences, and access to high-quality anticoagulation monitoring (ASA: Grade of Recommendation A, Level of Evidence Ia).
3. Warfarin (INR 2.0 to 3.0) is recommended for high-risk (4% annual risk of stroke) patients (and most moderate-risk patients according to an assessment of bleeding risk) with AF who have no clinically significant contraindications to oral anticoagulants (ASA: Grade of Recommendation A, Level of Evidence Ia).
4. Long-term oral anticoagulation therapy (target INR 2.5; range 2.0-3.0) should be considered for all AF patients at high risk of embolism: age >75 years, or age >60 years plus risk factors such as high blood pressure, left ventricular dysfunction, and diabetes mellitus (EUSI: Grade of Recommendation A, Level of Evidence Ia). C ombination therapy with aspirin 75-100 mg plus clopidogrel 75 mg daily, should be considered for stroke prevention in patients for whom there is patient refusal to take OAC therapy or a clear contraindication to OAC therapy (e.g. inability to cope or continue with anticoagulation monitoring), where there is a low risk of bleeding (Class IIa, LOE B).
2 011 AHA/ASA Guidelines for Primary Prevention of Stroke 11 F or high-risk patients with atrial fibrillation deemed unsuitable for anticoagulation, dual antiplatelet therapy with clopidogrel and aspirin offers more protection against stroke than aspirin alone but with increased risk of major bleeding and might be reasonable (Class IIb; LOE B). T he addition of clopidogrel to ASA to reduce the risk of major vascular events, including stroke, might be considered in patients with AF in whom oral anticoagulation with warfarin is considered unsuitable due to patient preference or the physician's assessment of the patient's ability to safely sustain anticoagulation (Class IIb, LOE B). 
Conflicts of Interest
The authors have no financial conflicts of interest. 
